PAVmed Inc. (PAVM)
| Market Cap | 45.03M +298.5% |
| Revenue (ttm) | 85,000 -95.7% |
| Net Income | -28.46M |
| EPS | -29.95 |
| Shares Out | 7.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,232 |
| Open | 6.34 |
| Previous Close | 6.39 |
| Day's Range | 6.15 - 6.34 |
| 52-Week Range | 6.00 - 28.44 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 40.50 (+548.0%) |
| Earnings Date | May 15, 2026 |
About PAVM
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price target is $40.5, which is an increase of 548.00% from the latest price.
News
PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year
Reports Q1 revenue $22,000 vs. $8,000 last year. PAVmed (PAVM) had cash and cash equivalents of $6.5M as of March 31, compared to $1.5M as of December 31, 2025. “PAVmed…
PAVmed Earnings Call Transcript: Q1 2026
Restructuring completed, simplifying capital structure and enabling growth across diversified life sciences segments. Lucid and Veris subsidiaries are advancing toward key milestones, with Lucid nearing Medicare coverage and Veris expanding its commercial rollout.
PAVmed Quarterly report: Q1 2026
PAVmed has published its Q1 2026 quarterly earnings report on May 15, 2026.
PAVmed Earnings release: Q1 2026
PAVmed released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
PAVmed Slides: Q1 2026
PAVmed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened ...
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement miles...
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, oper...
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diag...
PAVmed Proxy statement: Proxy filing
PAVmed filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
PAVmed Proxy statement: Proxy filing
PAVmed filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...
PAVmed Registration statement: Registration filing
PAVmed filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
PAVmed files to sell 9.23M shares of common stock for holders
06:04 EDT PAVmed (PAVM) files to sell 9.23M shares of common stock for holders
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed I...
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging ...
PAVmed price target lowered to $16 from $60 at Maxim
Maxim lowered the firm’s price target on PAVmed (PAVM) to $16 from $60 and keeps a Buy rating on the shares. The firm is adjusting its model on the stock…
PAVmed price target lowered to $16 from $60 at Maxim
Maxim lowered the firm’s price target on PAVmed (PAVM) to $16 from $60 and keeps a Buy rating on the shares. The firm is adjusting its model on the stock…
PAVmed Earnings Call Transcript: Q4 2025
Completed major restructuring and recapitalization, positioning for growth with a clean balance sheet and expanded MedTech portfolio. Lucid and Veris segments showed strong operational progress, with Lucid's revenue and test volumes up and Veris advancing its implantable device.
PAVmed Earnings release: Q4 2025
PAVmed released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
PAVmed Annual report: Q4 2025
PAVmed has published its Q4 2025 annual report on March 30, 2026.
PAVmed Slides: Q4 2025
PAVmed has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 30, 2026.
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological...
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with po...